The overwhelming evidence for 3rd shot boosters *before* Omicron, reinforced by new data for benefit vs Omicron 1. The randomized trial of 3 shots vs 2 shots + placebo, 95% efficacy for preventing symptomatic infections across all age 16+ groups (N=10,125) cdc.gov/vaccines/acip/…
3. Marked reduction of hospitalizations and deaths in over 728,321 people with 3 shots vs matched 728,321 people with 2 shots, across all age groups thelancet.com/action/showPdf…
4. Now vs Omicron, the variant with substantial immune escape, the 3rd shot induced a 25-fold increase in neutralizing antibody titer pfizer.com/news/press-rel…
Clinical correlation with effectiveness data and duration of impact pending
PS I am getting very tired of people ("experts," CDC, journalists) negating the incontrovertible evidence for 3rd shots that existed prior to Omicron, which is one of the reasons why less than 1 in 4 US adults have had boosters
• • •
Missing some Tweet in this thread? You can try to
force a refresh
New CDC genomic data shows continued rise of the KP.3 variant that accounts for 1 of 3 Covid cases.
LB.1 is gaining, too, as JN.1 fades away
This variant growth advantage plot by @BenjMurrell (H/T @siamosolocani) shows why this is the case. Note KP.3 is the one at far left w/ almost 3-fold advantage to JN.1.
Reinforces why the decision to develop the KP.2 vaccine booster (instead of JN.1) was a good one
Spike mutation map to show the differences betweem KP.3 and JN.1 (and LB.1, KP.2)
The connection between #SARSCoV2 and neurodegeneration
@TheLancetNeuro
Quotes below: 1. SARS-CoV-2 infection should be considered as a risk factor for Alzheimer’s disease, even though the distinction between causation versus disease acceleration is not clear.thelancet.com/journals/laneu…
2. Inflammation in patients with COVID-19, and controlled experiments show prolonged neuro-inflammation after mild SARS-CoV-2 infection
in macaques.
3. A direct correlation has been reported
between prior SARS-CoV-2 infection and increased risk
of Alzheimer’s disease (figure).
4. So far, the estimated lifetime cumulative risk of dementia due to hospitalisation for any viral infection is 1·48 (95% CI 1·15–1·91).
Breaking down the risks and benefit for lecanemab, the amyloid beta-directed antibody vs Alzheimer's drug approved @US_FDA last year. It doesn't look good.
My oped on the JN.1 variant and the 2nd biggest US wave of infections (after Omicron) since the pandemic began
@latimes @latimesopinion #LongCovid latimes.com/opinion/story/…
Recent @CDCgov #SARSCoV2 wastewater data for current wave (vs Omicron Jan 2022 and subsequent waves), graph by @luckytran
Sorry, @washingtonpost, but this is not "another Covid-19 uptick" as you put it in your Health Alert. You ignore the best metric for infections that we have at present—wastewater—focusing only on hospitalizations washingtonpost.com/health/2024/01…
3 New #LongCovid reports 1. Vaccination protection—1 dose 21%, 2 doses 59%, 3 doses 73% among ~590,000 people in Sweden (strong association) bmj.com/content/383/bm…
2. 3-year prospective follow up of a cohort of ~1350 participants, hospitalized in China
—Lung function restored back to baseline in most
—Higher risk of reinfection that people w/o Long Covid
—Half w/ persistent symptoms thelancet.com/journals/lanre…
3. At @RSNA annual meeting, brain MRI with microstructure imaging (DMI), participants with #LongCovid vs controls had microstructure changes associated with impaired cognition, sense of smell and fatigue eurekalert.org/news-releases/…